Research map: Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD )

Back to the article

Papers in this map

  1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Paul E. Stevens · 2024 · 8239 citations · Cited by this paper
  2. Economic Impact of Multidisciplinary Pre‐operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non‐cardiac Surgery in Australia: A Trial‐Based Analysis · 2026 · Related
  3. Dapagliflozin in Patients with Chronic Kidney Disease · Hiddo J.L. Heerspink · 2020 · 5532 citations · Cited by this paper
  4. Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease · 2026 · Related
  5. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes · George L. Bakris · 2020 · 2886 citations · Cited by this paper
  6. Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy · 2026 · Related
  7. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  8. Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive‐Age Women in the United States · 2026 · Related
  9. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes · Bertram Pitt · 2021 · 1742 citations · Cited by this paper
  10. Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study · 2026 · Related
  11. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis · Rajiv Agarwal · 2021 · 1298 citations · Cited by this paper
  12. Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment‐Resistant Non‐Diabetic Obesity: A Retrospective Pilot Study · 2026 · Related
  13. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency · Andrew S. Levey · 2019 · 601 citations · Cited by this paper
  14. Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non‐Insulin Treated Type 2 Diabetes: A Randomised Trial · 2026 · Related
  15. First Morning Voids Are More Reliable Than Spot Urine Samples to Assess Microalbuminuria · Elsbeth C. Witte · 2008 · 293 citations · Cited by this paper
  16. Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease · 2026 · Related
  17. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes · Rajiv Agarwal · 2025 · 284 citations · Cited by this paper
  18. Methodological and Conceptual Concerns Regarding the 24‐h Glycaemia/C‐Peptide Ratio as a Novel Insulin Sensitivity Index · 2026 · Related
  19. Development of Risk Prediction Equations for Incident Chronic Kidney Disease · Robert G. Nelson · 2019 · 255 citations · Cited by this paper
  20. Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte · 2026 · Related
  21. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial · Rajiv Agarwal · 2021 · 254 citations · Cited by this paper
  22. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk · Mansoor Husain · 2020 · 215 citations · Cited by this paper
  23. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets · Jonatan Barrera‐Chimal · 2020 · 180 citations · Cited by this paper
  24. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials · Ajay Chaudhuri · 2021 · 125 citations · Cited by this paper
  25. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review · Sophie Elizabeth Claudel · 2025 · 110 citations · Cited by this paper
  26. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study · Luis Miguel Ruilope · 2022 · 81 citations · Cited by this paper
  27. Cardiovascular Disease in Diabetes and Chronic Kidney Disease · Sowmya Swamy · 2023 · 75 citations · Cited by this paper
  28. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus · Ruolin Lv · 2023 · 65 citations · Cited by this paper
  29. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use · Peter R Rossing · 2022 · 45 citations · Cited by this paper
  30. The relationship between diabetic retinopathy and diabetic nephropathy in type 2 diabetes · Qian Wang · 2024 · 39 citations · Cited by this paper
  31. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists · Christian W. Mende · 2023 · 36 citations · Cited by this paper
  32. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial · Mary E. Branch · 2019 · 29 citations · Cited by this paper
  33. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice · Nihar R. Desai · 2023 · 29 citations · Cited by this paper
  34. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases · Wen‐Ming Chen · 2023 · 22 citations · Cited by this paper
  35. The intersection of mineralocorticoid receptor activation and the FGF23–Klotho cascade: a duopoly that promotes renal and cardiovascular injury · Murray Epstein · 2021 · 16 citations · Cited by this paper
  36. Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform · Atsuhisa Sato · 2024 · 16 citations · Cited by this paper
  37. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease · John W. Ostrominski · 2025 · 16 citations · Cited by this paper
  38. Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease? · Óscar Moreno · 2024 · 14 citations · Cited by this paper
  39. Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform · Csaba Pal Kovesdy · 2025 · 13 citations · Cited by this paper

Source: OpenAlex (CC0)